In a study by Weickhardt et al., an analysis of patients with EGFR- or ALK-mutated NSCLC under tyrosine kinase inhibitor (TKI) therapy showed a successful application of LAT for oligoprogression with a median of more than 6 months of disease control after LAT [59]. This evidence concerns the gene LAT and non-small cell lung carcinoma.